Latest Data from Phase I/II Study Reported in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025 and Published Concurrently in Nature Medicine VT3989 Achieves 32% Overall Response Rate, 86% Disease Control Rate, and 40 Weeks of Median Progression-Free...
Hence then, the article about vt3989 vivace therapeutics best in class hippo pathway targeting therapy demonstrates promising antitumor activity in refractory mesothelioma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma )
Also on site :
- US cybersecurity chief leaked sensitive files to ChatGPT – Politico
- Merz rejects Zelensky’s ‘concrete date’ for EU membership
- Driver ‘intentionally’ rams car into synagogue in New York (VIDEO)